Fresenius Kabi announced today the immediate availability in the United States of Remifentanil Hydrochloride for Injection. Fresenius Kabi Remifentanil for Injection is available as a lyophilized powder in three presentations: 1mg in a 3mL vial; 2 mg in a 5 mL vial and 5mg in a 10 mL vial.
“Fresenius Kabi has been investing significantly in product development over the last several years, and plans to launch multiple generic injectable products in the U.S. this year,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are pleased to announce the introduction of Remifentanil, a first – and lower cost – alternative for anesthesia clinicians.”
Fresenius Kabi offers a broad portfolio of anesthesia and analgesia medicines for injection.
Remifentanil HCl for Injection is indicated for IV administration as an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; for continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting and as an analgesic component of monitored anesthesia care in adult patients.